Сравнительная характеристика токсичности противоопухолевых антибиотиков группы актиномицинов при лечении солидных опухолей у детей (Т.В. Горбунова, И.В. Березовская, Т.В. Постникова)

Introduction. Toxic reactions to actinomycin D found not uncommon and can be often. However, side effects are usually reversible upon discontinuation of treatment. The aim of our study was to compare the clinical toxicity Kosmegen (production Merck Sharp & Dohme, UK) and the drug Aknomid D (LLC «Adik», Russia ), used in various modes of chemotherapy in children with solid tumors. Materials and Methods. The study included 38 patients, from 5 months to 16 years under observation and treated with the inclusion of drug regimens Aknomid-D and Kosmegen in the Institute of Children Oncology from 2011 to 2013. Toxicity assessment was carried out on the international scale of the Modified SIOP acute and subacute toxicity. Results. In general, patients in both groups dominated myelotoxicity, wherein the 3−4 degree myelotoxicity was recorded during the first course of chemotherapy with the same frequency. Hepatotoxicity was detected more frequently in the group of patients who were given the Kosmegen, but in this group are no reported cases of serious liver injury (grade 4). There was an increase of transaminases (ALT, AST) up to 10 standards in patients in both groups. Emetic syndrome developed with the same frequency in both groups of patients. Intensity emetic syndrome did not differ. Conclusion. Domestic drug Aknonid-D in the study showed good tolerance by patients and can be recommended for use in the Russian Federation. Keywords: Kosmegen, Aknomid D, toxicity, children. (Onkopediatriya – Oncopediatrics. 2014; 1: 20-24)